Myriad Genetics (MYGN) Financials

Myriad Genetics logo
$5.57 -0.09 (-1.59%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$5.64 +0.06 (+1.17%)
As of 05:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Myriad Genetics

Annual Income Statements for Myriad Genetics

This table shows Myriad Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
80 117 17 133 4.60 -200 -27 -112 -263 -127 -366
Consolidated Net Income / (Loss)
80 117 17 133 4.40 -200 -27 -112 -263 -127 -366
Net Income / (Loss) Continuing Operations
80 117 17 133 4.40 -200 -27 -112 -263 -127 -366
Total Pre-Tax Income
134 156 36 120 0.00 -223 -57 -141 -262 -124 -395
Total Operating Income
134 153 44 122 7.60 -232 -191 -141 -257 -124 -387
Total Gross Profit
575 583 558 567 650 453 493 476 517 585 577
Total Revenue
723 741 729 744 851 639 691 678 753 838 825
Operating Revenue
723 741 729 744 851 639 691 678 753 838 825
Total Cost of Revenue
147 157 171 177 201 186 198 202 236 252 248
Operating Cost of Revenue
147 157 171 177 201 186 198 202 236 252 248
Total Operating Expenses
442 430 514 445 643 684 684 617 774 709 964
Selling, General & Admin Expense
366 359 440 435 557 507 538 248 284 276 257
Marketing Expense
- - - - - - - 267 289 284 281
Research & Development Expense
76 71 74 71 86 77 82 85 89 113 107
Other Operating Expenses / (Income)
- - - - - - - 0.00 113 -21 0.00
Impairment Charge
- - - 0.00 0.00 100 1.80 17 0.00 57 319
Total Other Income / (Expense), net
0.70 2.60 -7.80 -1.80 -7.60 8.40 133 0.00 -4.80 0.00 -7.90
Interest Expense
0.20 0.30 6.00 3.20 12 11 6.60 3.20 2.90 2.80 11
Interest & Investment Income
0.40 0.90 1.20 1.80 3.20 3.00 0.70 2.60 2.50 1.70 1.80
Other Income / (Expense), net
0.50 2.00 -3.00 -0.40 1.20 16 139 0.60 -4.40 1.10 0.80
Income Tax Expense
55 39 19 -13 -4.40 -24 -30 -29 1.10 3.80 -29
Basic Earnings per Share
$1.12 $1.67 $0.25 $1.92 $0.06 ($2.69) ($0.35) ($1.39) ($3.18) ($1.41) ($3.95)
Weighted Average Basic Shares Outstanding
71.30M 70M 68.30M 69.40M 73.50M 74.30M 78M 80.60M 82.80M 90.60M 92.60M
Diluted Earnings per Share
$1.07 $1.60 $0.25 $1.85 $0.06 ($2.69) ($0.35) ($1.39) ($3.18) ($1.41) ($3.95)
Weighted Average Diluted Shares Outstanding
74.50M 73.40M 68.80M 72M 76M 74.30M 78M 80.60M 82.80M 90.60M 92.60M
Weighted Average Basic & Diluted Shares Outstanding
71.60M 70M -1.03B 69.40M 76.70M 74.71M 80.02M 81.22M 89.87M 91.31M 93.51M

Quarterly Income Statements for Myriad Genetics

This table shows Myriad Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-26 -37 -22 -43 -0.10 -331 -27 -7.90 -34 -43 -44
Consolidated Net Income / (Loss)
-26 -37 -22 -43 -0.10 -331 -27 -7.90 -34 -43 -44
Net Income / (Loss) Continuing Operations
-26 -37 -22 -43 -0.10 -331 -27 -7.90 -34 -43 -44
Total Pre-Tax Income
-26 -37 -21 -39 -29 -331 -26 -8.90 -34 -43 -44
Total Operating Income
-28 -37 -20 -39 -29 -329 -23 -5.70 -31 -39 -40
Total Gross Profit
138 147 150 151 134 152 144 147 138 127 138
Total Revenue
202 212 213 211 196 213 206 210 200 191 203
Operating Revenue
202 212 213 211 196 213 206 210 200 191 203
Total Cost of Revenue
65 64 64 60 62 61 62 63 63 64 65
Operating Cost of Revenue
65 64 64 60 62 61 62 63 63 64 65
Total Operating Expenses
166 184 170 190 163 481 167 153 168 166 178
Selling, General & Admin Expense
71 72 69 -149 67 67 68 56 62 58 67
Marketing Expense
69 73 70 - 69 72 71 69 74 83 84
Research & Development Expense
25 27 29 33 28 26 28 26 27 25 27
Impairment Charge
- 12 2.20 - 0.00 317 0.00 2.70 5.40 0.00 0.00
Total Other Income / (Expense), net
2.00 -0.70 -1.20 -0.10 -0.40 -1.40 -2.90 -3.20 -3.40 -3.70 -3.70
Interest Expense
0.50 0.80 0.80 0.70 0.80 1.50 3.80 4.40 4.10 4.10 4.10
Interest & Investment Income
0.60 0.40 0.40 0.30 0.30 0.20 0.50 0.80 0.70 0.40 0.60
Other Income / (Expense), net
1.90 -0.30 -0.80 0.30 0.10 -0.10 0.40 0.40 0.00 0.00 -0.20
Income Tax Expense
0.10 -0.50 0.90 3.30 -29 -0.10 1.20 -1.00 0.00 0.60 0.30
Basic Earnings per Share
($0.29) ($0.41) ($0.24) ($0.47) $0.00 ($3.57) ($0.29) ($0.09) ($0.36) ($0.46) ($0.46)
Weighted Average Basic Shares Outstanding
89.90M 90.60M 90.90M 90.60M 91.40M 92.50M 93.10M 92.60M 93.70M 94.80M 95.70M
Diluted Earnings per Share
($0.29) ($0.41) ($0.24) ($0.47) $0.00 ($3.57) ($0.29) ($0.09) ($0.36) ($0.46) ($0.46)
Weighted Average Diluted Shares Outstanding
89.90M 90.60M 90.90M 90.60M 91.40M 92.50M 93.10M 92.60M 93.70M 94.80M 95.70M
Weighted Average Basic & Diluted Shares Outstanding
90.51M 90.82M 91.04M 91.31M 92.18M 93.04M 93.21M 93.51M 94.45M 95.65M 95.92M

Annual Cash Flow Statements for Myriad Genetics

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-0.70 4.40 34 9.30 -18 71 142 -192 75 -29 39
Net Cash From Operating Activities
141 166 106 116 84 61 19 -106 -111 -8.70 1.80
Net Cash From Continuing Operating Activities
141 166 106 116 84 61 19 -106 -111 -8.70 1.80
Net Income / (Loss) Continuing Operations
80 117 17 133 4.60 -200 -27 -112 -263 -127 -366
Consolidated Net Income / (Loss)
80 117 17 133 4.60 -200 -27 -112 -263 -127 -366
Depreciation Expense
25 27 48 54 73 72 63 53 62 61 54
Non-Cash Adjustments To Reconcile Net Income
74 64 34 7.70 32 124 -105 85 76 111 362
Changes in Operating Assets and Liabilities, net
-39 -42 6.80 -80 -26 64 88 -132 15 -53 -48
Net Cash From Investing Activities
41 -91 -146 -12 -286 19 274 -78 32 -12 -27
Net Cash From Continuing Investing Activities
41 -91 -146 -12 -286 19 274 -78 32 -12 -27
Purchase of Property, Plant & Equipment
-24 -5.00 -6.10 -8.40 -8.60 -10 -18 -45 -63 -19 -16
Acquisitions
-20 -37 -216 0.00 -279 0.00 0.00 -57 -10 -11 -12
Divestitures
- - - 0.00 0.00 21 379 0.00 0.00 8.80 0.00
Sale and/or Maturity of Investments
166 115 163 78 79 69 61 128 105 9.00 0.00
Net Cash From Financing Activities
-177 -68 72 -95 182 -10 -151 -8.00 153 -7.40 64
Net Cash From Continuing Financing Activities
-177 -68 72 -95 182 -10 -151 -8.00 153 -7.40 64
Repayment of Debt
- - -306 -143 -116 -9.60 -228 -0.70 -42 -120 -89
Issuance of Debt
30 94 409 53 340 - 0.00 0.00 80 120 165
Issuance of Common Equity
- - - 46 23 13 92 6.30 124 5.90 3.30
Other Financing Activities, net
3.40 - - -51 -15 -14 -15 -14 -8.80 -13 -15

Quarterly Cash Flow Statements for Myriad Genetics

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-35 -4.40 8.60 2.10 -11 -17 71 -4.30 -25 -22 -18
Net Cash From Operating Activities
-19 2.60 0.70 6.60 -16 -14 21 11 -16 -8.30 -6.50
Net Cash From Continuing Operating Activities
-19 2.60 0.70 6.60 -16 -14 21 11 -16 -21 -16
Net Income / (Loss) Continuing Operations
-26 -37 -22 -43 -0.10 -331 -27 -7.90 -34 -43 -44
Consolidated Net Income / (Loss)
-26 -37 -22 -43 -0.10 -331 -27 -7.90 -34 -43 -44
Depreciation Expense
16 15 16 15 14 14 13 13 13 13 13
Non-Cash Adjustments To Reconcile Net Income
9.00 28 15 58 12 330 13 6.60 13 -4.70 1.30
Changes in Operating Assets and Liabilities, net
-17 -3.30 -8.20 -23 -43 -27 23 -0.70 -7.00 14 15
Net Cash From Investing Activities
-7.10 -6.40 7.50 -5.90 -8.30 -6.90 -6.20 -6.00 -6.50 -3.20 -2.10
Net Cash From Continuing Investing Activities
-7.10 -6.40 7.50 -5.90 -8.30 -6.90 -6.20 -6.00 -6.50 -3.20 -2.10
Purchase of Property, Plant & Equipment
-6.70 -8.90 -6.30 -5.90 -5.30 -2.80 -2.80 -4.70 -5.40 -2.10 -1.80
Acquisitions
-1.90 - - - -3.00 -4.10 -3.40 -1.30 -1.10 -1.10 -0.30
Net Cash From Financing Activities
-8.80 2.40 -3.10 2.10 14 2.60 56 -8.20 -3.00 2.20 -0.30
Net Cash From Continuing Financing Activities
-8.80 2.40 -3.10 2.10 14 2.60 56 -8.20 -3.00 2.20 -0.30
Other Financing Activities, net
-8.80 -0.60 -3.10 -1.30 -5.90 -0.10 -0.40 -8.40 -3.00 -0.60 -0.30

Annual Balance Sheets for Myriad Genetics

This table presents Myriad Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
766 881 1,209 1,175 1,563 1,419 1,321 1,199 1,147 1,028 707
Total Current Assets
284 315 302 328 349 389 485 275 314 298 333
Cash & Equivalents
64 69 102 111 93 117 257 57 132 102 150
Accounts Receivable
88 95 96 103 139 90 91 102 114 121 115
Inventories, net
25 38 42 34 31 27 15 20 22 28 31
Prepaid Expenses
13 18 13 9.40 17 14 21 20 19 31 25
Current Deferred & Refundable Income Taxes
14 3.80 0.20 - 25 108 18 18 17 16 12
Plant, Property, & Equipment, net
67 58 51 43 57 41 44 83 119 117 114
Total Noncurrent Assets
415 508 856 805 1,157 989 792 841 714 612 260
Goodwill
177 195 316 319 417 329 239 287 287 286 52
Intangible Assets
193 228 492 455 685 577 404 380 350 262 153
Other Noncurrent Operating Assets
5.00 5.00 - - 0.00 62 90 119 77 64 55
Total Liabilities & Shareholders' Equity
766 881 1,209 1,175 1,563 1,419 1,321 1,199 1,147 1,028 707
Total Liabilities
104 132 441 209 474 538 353 313 363 327 339
Total Current Liabilities
69 72 218 102 118 146 204 137 156 164 134
Accounts Payable
21 21 22 26 33 21 30 29 26 32 30
Accrued Expenses
46 50 66 68 82 79 162 94 114 119 97
Other Current Liabilities
- - - - 0.00 14 13 14 16 13 6.90
Total Noncurrent Liabilities
35 60 223 107 356 392 149 176 207 162 205
Long-Term Debt
8.80 7.80 106 16 234 225 - 0.00 39 40 120
Other Noncurrent Operating Liabilities
- 10 13 9.20 40 96 85 149 139 90 85
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
662 748 768 966 1,089 881 968 886 783 701 368
Total Preferred & Common Equity
662 748 768 966 1,089 881 968 886 783 701 368
Total Common Equity
662 748 768 966 1,089 881 968 886 783 701 368
Common Stock
746 831 852 916 1,069 1,110 1,227 1,261 1,416 1,459 1,490
Retained Earnings
-77 -73 -78 54 26 -227 -254 -366 -630 -757 -1,123
Accumulated Other Comprehensive Income / (Loss)
-7.00 -9.50 -5.50 -4.10 -5.40 -2.30 -5.10 -8.90 -3.70 -0.80 0.80

Quarterly Balance Sheets for Myriad Genetics

This table presents Myriad Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
1,187 1,149 1,111 1,085 1,081 1,006 677 728 674 639 609
Total Current Assets
294 265 290 292 293 287 284 345 313 289 272
Cash & Equivalents
103 76 97 92 100 92 74 145 124 115 107
Accounts Receivable
112 115 118 118 126 120 137 118 124 110 106
Inventories, net
23 25 25 26 26 28 29 32 28 31 29
Prepaid Expenses
21 21 25 22 24 32 30 36 35 32 29
Current Deferred & Refundable Income Taxes
18 18 18 18 17 14 14 14 2.00 1.80 1.50
Plant, Property, & Equipment, net
112 121 119 116 115 114 113 111 112 109 105
Total Noncurrent Assets
781 763 702 677 673 605 280 272 249 241 233
Goodwill
287 287 287 286 286 286 52 52 47 47 47
Intangible Assets
359 357 341 320 313 258 170 163 146 139 132
Other Noncurrent Operating Assets
129 120 74 71 74 61 58 57 57 55 54
Total Liabilities & Shareholders' Equity
1,187 1,149 1,111 1,085 1,081 1,006 677 728 674 639 609
Total Liabilities
452 466 351 345 350 301 289 355 336 335 340
Total Current Liabilities
221 209 146 149 154 151 200 148 130 131 138
Accounts Payable
40 34 33 33 30 28 31 32 33 30 28
Accrued Expenses
164 158 99 98 111 112 101 108 91 93 102
Other Current Liabilities
17 18 14 13 14 11 9.00 7.90 7.10 7.30 7.80
Total Noncurrent Liabilities
231 256 204 196 195 150 89 207 206 204 203
Long-Term Debt
38 39 39 39 39 59 0.00 120 120 121 121
Other Noncurrent Operating Liabilities
160 186 135 126 125 89 88 87 86 84 82
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
735 683 760 741 732 705 388 373 337 304 269
Total Preferred & Common Equity
735 683 760 741 732 705 388 373 337 304 269
Total Common Equity
735 683 760 741 732 705 388 373 337 304 269
Common Stock
1,278 1,287 1,420 1,437 1,446 1,462 1,476 1,488 1,494 1,503 1,512
Retained Earnings
-537 -598 -656 -692 -714 -757 -1,087 -1,115 -1,157 -1,200 -1,244
Accumulated Other Comprehensive Income / (Loss)
-5.40 -5.30 -4.20 -4.00 -0.10 -0.60 -0.10 -0.10 0.70 0.80 0.70

Annual Metrics And Ratios for Myriad Genetics

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
69,451,234.00 70,298,970.00 68,118,450.00 69,906,818.00 73,373,443.00 74,554,701.00 79,854,649.00 - - - 93,213,722.00
DEI Adjusted Shares Outstanding
69,451,234.00 70,298,970.00 68,118,450.00 69,906,818.00 73,373,443.00 74,554,701.00 79,854,649.00 - - - 93,213,722.00
DEI Earnings Per Adjusted Shares Outstanding
1.15 1.67 0.26 1.91 0.06 -2.68 -0.34 - - - -3.93
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-7.16% 2.49% -1.59% 2.06% 14.44% -24.97% 8.14% -1.77% 11.03% 11.21% -1.56%
EBITDA Growth
-44.41% 14.52% -50.99% 96.98% -53.50% -275.43% 108.08% -852.59% -116.04% 67.55% -443.63%
EBIT Growth
-50.77% 15.88% -73.62% 196.34% -92.76% -2,548.86% 76.24% -173.44% -87.00% 53.25% -215.69%
NOPAT Growth
-54.39% 45.18% -81.86% 546.20% -96.06% -3,148.68% 17.78% 26.19% -83.07% 52.02% -213.52%
Net Income Growth
-54.71% 46.87% -85.32% 673.84% -96.69% -4,636.36% 86.37% -311.76% -135.09% 51.65% -187.43%
EPS Growth
-52.44% 49.53% -84.38% 640.00% -96.76% -4,583.33% 86.99% -297.14% -128.78% 55.66% -180.14%
Operating Cash Flow Growth
-26.13% 18.36% -36.14% 9.13% -27.78% -27.48% -69.36% -671.51% -4.33% 92.16% 120.69%
Free Cash Flow Firm Growth
155.10% 97.59% -415.83% 161.17% -316.06% 109.81% 572.54% -205.97% 40.75% 69.66% 165.89%
Invested Capital Growth
8.25% 6.49% 55.20% -3.33% 45.75% -17.38% -38.98% 25.63% -4.93% -6.24% -47.00%
Revenue Q/Q Growth
0.08% -2.13% -2.07% 5.10% 2.59% -0.23% -7.14% 2.57% 2.56% 1.70% -0.10%
EBITDA Q/Q Growth
-9.18% -5.55% -5.00% 4.39% -18.77% -128.87% 130.53% -11.07% 14.81% -12.92% 8.60%
EBIT Q/Q Growth
-11.35% -6.55% -21.46% 4.83% -71.61% -60.34% 51.79% -6.95% 7.13% -5.79% 7.98%
NOPAT Q/Q Growth
-16.07% -4.32% -20.50% 3.29% -80.99% -72.40% 23.89% -6.92% 7.48% -6.65% 7.94%
Net Income Q/Q Growth
-16.00% -2.58% -28.93% 4.89% -81.03% -108.79% 78.73% -44.89% 4.05% -9.74% 8.64%
EPS Q/Q Growth
-14.40% -2.44% -26.47% 2.78% -78.57% -111.81% 80.00% -47.87% 5.36% -10.16% 8.78%
Operating Cash Flow Q/Q Growth
7.73% -6.99% -1.76% 10.80% -16.38% 219.47% -81.64% 2.03% -74.65% 87.57% 181.82%
Free Cash Flow Firm Q/Q Growth
-7.55% -31.47% 13.87% 22.21% -11.04% -65.97% -4.29% -25.68% 16.23% 62.20% -1.76%
Invested Capital Q/Q Growth
-1.57% 5.19% -2.73% -5.78% -3.04% -3.82% 2.72% 8.93% 7.11% -4.85% -2.48%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
79.60% 78.76% 76.51% 76.17% 76.38% 70.86% 71.39% 70.22% 68.64% 69.89% 69.93%
EBITDA Margin
22.02% 24.61% 12.25% 23.65% 9.61% -22.47% 1.68% -12.87% -25.04% -7.31% -40.35%
Operating Margin
18.49% 20.72% 6.04% 16.39% 0.89% -36.28% -27.58% -20.73% -34.17% -14.74% -46.96%
EBIT Margin
18.56% 20.99% 5.63% 16.34% 1.03% -33.75% -7.41% -20.64% -34.76% -14.61% -46.86%
Profit (Net Income) Margin
11.05% 15.83% 2.36% 17.90% 0.52% -31.26% -3.94% -16.51% -34.96% -15.20% -44.38%
Tax Burden Percent
59.42% 75.13% 47.51% 110.82% 0.00% 89.39% 47.64% 79.66% 100.42% 103.08% 92.61%
Interest Burden Percent
100.15% 100.39% 88.29% 98.85% 0.00% 103.62% 111.52% 100.43% 100.15% 100.90% 102.25%
Effective Tax Rate
40.58% 24.87% 52.49% -10.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
17.00% 22.99% 3.17% 17.12% 0.56% -15.71% -17.73% -15.31% -25.80% -13.11% -55.51%
ROIC Less NNEP Spread (ROIC-NNEP)
16.81% 22.03% 6.94% 19.68% 1.80% -94.63% -79.32% -10.52% 35.30% 36.35% 149.60%
Return on Net Nonoperating Assets (RNNOA)
-5.44% -6.37% -0.90% -1.77% -0.13% -4.55% 14.79% 3.22% -5.75% -4.05% -12.94%
Return on Equity (ROE)
11.56% 16.62% 2.27% 15.35% 0.43% -20.27% -2.94% -12.08% -31.55% -17.15% -68.45%
Cash Return on Invested Capital (CROIC)
9.08% 16.71% -40.09% 20.51% -36.68% 3.32% 30.68% -38.03% -20.74% -6.66% 5.93%
Operating Return on Assets (OROA)
16.87% 18.87% 3.92% 10.19% 0.64% -14.46% -3.74% -11.11% -22.33% -11.26% -44.56%
Return on Assets (ROA)
10.04% 14.23% 1.65% 11.17% 0.32% -13.39% -1.99% -8.89% -22.45% -11.71% -42.20%
Return on Common Equity (ROCE)
11.56% 16.62% 2.27% 15.35% 0.43% -20.27% -2.94% -12.08% -31.55% -17.15% -68.45%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12.64% -33.62% -18.16% 0.00%
Net Operating Profit after Tax (NOPAT)
79 115 21 135 5.32 -162 -133 -98 -180 -86 -271
NOPAT Margin
10.99% 15.56% 2.87% 18.17% 0.63% -25.40% -19.31% -14.51% -23.92% -10.32% -32.87%
Net Nonoperating Expense Percent (NNEP)
0.19% 0.96% -3.77% -2.56% -1.24% 78.92% 61.59% -4.79% -61.10% -49.46% -205.10%
Return On Investment Capital (ROIC_SIMPLE)
11.83% 15.25% 2.09% 13.69% 0.40% -14.67% -13.78% -11.11% -21.93% -11.67% -55.55%
Cost of Revenue to Revenue
20.40% 21.24% 23.49% 23.83% 23.62% 29.14% 28.61% 29.78% 31.36% 30.11% 30.07%
SG&A Expenses to Revenue
50.66% 48.51% 60.37% 58.49% 65.40% 79.44% 77.87% 36.54% 37.67% 32.94% 31.15%
R&D to Revenue
10.45% 9.53% 10.21% 9.52% 10.09% 12.09% 11.86% 12.59% 11.78% 13.54% 12.95%
Operating Expenses to Revenue
61.11% 58.04% 70.47% 59.78% 75.49% 107.14% 98.97% 90.95% 102.81% 84.63% 116.90%
Earnings before Interest and Taxes (EBIT)
134 155 41 122 8.80 -216 -51 -140 -262 -122 -386
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
159 182 89 176 82 -144 12 -87 -189 -61 -333
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.57 2.88 2.29 2.70 1.87 0.96 2.28 1.33 2.01 1.78 1.56
Price to Tangible Book Value (P/TBV)
8.08 6.61 0.00 13.59 0.00 0.00 6.79 5.36 10.75 8.19 3.52
Price to Revenue (P/Rev)
3.27 2.91 2.42 3.51 2.39 1.32 3.19 1.73 2.09 1.49 0.70
Price to Earnings (P/E)
29.58 18.35 101.16 19.60 443.11 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
3.38% 5.45% 0.99% 5.10% 0.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
4.50 3.71 2.24 3.12 1.84 0.96 3.17 1.41 2.16 1.86 1.61
Enterprise Value to Revenue (EV/Rev)
3.02 2.59 2.46 3.26 2.44 1.41 2.62 1.48 1.95 1.42 0.66
Enterprise Value to EBITDA (EV/EBITDA)
13.73 10.54 20.09 13.77 25.43 0.00 155.71 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
16.29 12.36 43.76 19.93 236.37 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
27.51 16.66 85.82 17.93 390.98 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
15.54 11.55 16.89 20.90 24.85 14.80 97.11 0.00 0.00 0.00 301.98
Enterprise Value to Free Cash Flow (EV/FCFF)
51.53 22.93 0.00 14.97 0.00 26.19 7.83 0.00 0.00 0.00 18.77
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.01 0.01 0.30 0.02 0.21 0.26 0.00 0.00 0.05 0.06 0.33
Long-Term Debt to Equity
0.01 0.01 0.14 0.02 0.21 0.26 0.00 0.00 0.05 0.06 0.33
Financial Leverage
-0.32 -0.29 -0.13 -0.09 -0.07 0.05 -0.19 -0.31 -0.16 -0.11 -0.09
Leverage Ratio
1.15 1.17 1.38 1.37 1.33 1.51 1.48 1.36 1.41 1.46 1.62
Compound Leverage Factor
1.15 1.17 1.22 1.36 0.00 1.57 1.65 1.37 1.41 1.48 1.66
Debt to Total Capital
1.31% 1.03% 23.32% 2.12% 17.66% 20.33% 0.00% 0.00% 4.69% 5.35% 24.57%
Short-Term Debt to Total Capital
0.00% 0.00% 12.71% 0.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
1.31% 1.03% 10.61% 1.58% 17.66% 20.33% 0.00% 0.00% 4.69% 5.35% 24.57%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% -0.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
98.69% 98.97% 76.72% 97.88% 82.34% 79.67% 100.00% 100.00% 95.31% 94.65% 75.43%
Debt to EBITDA
0.06 0.04 2.62 0.12 2.85 -1.57 0.00 0.00 -0.20 -0.65 -0.36
Net Debt to EBITDA
-1.11 -1.27 0.39 -1.08 0.51 -0.37 0.00 0.00 0.54 1.03 0.09
Long-Term Debt to EBITDA
0.06 0.04 1.19 0.09 2.85 -1.57 0.00 0.00 -0.20 -0.65 -0.36
Debt to NOPAT
0.11 0.07 11.17 0.15 43.89 -1.39 0.00 0.00 -0.21 -0.46 -0.44
Net Debt to NOPAT
-2.22 -2.01 1.65 -1.41 7.84 -0.33 0.00 0.00 0.57 0.73 0.11
Long-Term Debt to NOPAT
0.11 0.07 5.08 0.12 43.89 -1.39 0.00 0.00 -0.21 -0.46 -0.44
Altman Z-Score
15.32 11.39 3.10 8.76 3.34 0.87 4.13 2.15 1.90 1.84 -1.51
Noncontrolling Interest Sharing Ratio
0.00% 0.00% -0.03% -0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.13 4.35 1.39 3.21 2.96 2.67 2.37 2.00 2.01 1.82 2.49
Quick Ratio
3.38 3.51 1.13 2.78 2.34 1.65 2.11 1.58 1.64 1.36 1.98
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
42 84 -264 162 -350 34 231 -245 -145 -44 29
Operating Cash Flow to CapEx
587.87% 3,326.00% 1,740.98% 1,379.76% 973.26% 595.10% 103.33% -234.66% -151.30% -29.29% 11.54%
Free Cash Flow to Firm to Interest Expense
211.92 279.16 -44.08 50.56 -29.13 3.18 34.96 -76.41 -49.96 -15.70 2.76
Operating Cash Flow to Interest Expense
702.50 554.33 17.70 36.22 6.98 5.62 2.82 -33.22 -38.24 -3.11 0.17
Operating Cash Flow Less CapEx to Interest Expense
583.00 537.67 16.68 33.59 6.26 4.68 0.09 -47.38 -63.52 -13.71 -1.31
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.91 0.90 0.70 0.62 0.62 0.43 0.50 0.54 0.64 0.77 0.95
Accounts Receivable Turnover
8.36 8.11 7.63 7.47 7.04 5.60 7.64 7.03 6.98 7.11 6.97
Inventory Turnover
6.02 4.96 4.25 4.63 6.12 6.36 9.32 11.41 11.22 10.19 8.53
Fixed Asset Turnover
14.19 11.80 13.32 15.77 16.94 13.03 16.40 10.69 7.44 7.09 7.13
Accounts Payable Turnover
6.67 7.46 7.94 7.38 6.78 6.92 7.89 6.92 8.65 8.68 7.96
Days Sales Outstanding (DSO)
43.65 45.03 47.81 48.88 51.87 65.19 47.78 51.89 52.31 51.31 52.35
Days Inventory Outstanding (DIO)
60.67 73.56 85.81 78.79 59.65 57.37 39.16 31.98 32.53 35.82 42.77
Days Payable Outstanding (DPO)
54.73 48.96 45.94 49.44 53.84 52.76 46.27 52.76 42.19 42.04 45.86
Cash Conversion Cycle (CCC)
49.59 69.62 87.68 78.24 57.68 69.80 40.67 31.11 42.65 45.09 49.26
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
486 517 802 776 1,131 934 570 716 681 638 338
Invested Capital Turnover
1.55 1.48 1.10 0.94 0.89 0.62 0.92 1.06 1.08 1.27 1.69
Increase / (Decrease) in Invested Capital
37 32 285 -27 355 -197 -364 146 -35 -43 -300
Enterprise Value (EV)
2,184 1,920 1,794 2,422 2,080 899 1,806 1,006 1,471 1,185 544
Market Capitalization
2,361 2,151 1,760 2,612 2,038 845 2,204 1,176 1,573 1,248 573
Book Value per Share
$9.53 $10.64 $11.28 $13.82 $14.84 $11.82 $12.12 $10.93 $9.53 $7.70 $3.95
Tangible Book Value per Share
$4.21 $4.63 ($0.58) $2.75 ($0.18) ($0.33) $4.06 $2.71 $1.78 $1.67 $1.75
Total Capital
671 756 1,002 987 1,322 1,106 968 886 822 741 488
Total Debt
8.80 7.80 234 21 234 225 0.00 0.00 39 40 120
Total Long-Term Debt
8.80 7.80 106 16 234 225 0.00 0.00 39 40 120
Net Debt
-177 -231 34 -190 42 53 -398 -170 -102 -63 -30
Capital Expenditures (CapEx)
24 5.00 6.10 8.40 8.60 10 18 45 73 30 16
Debt-free, Cash-free Net Working Capital (DFCFNWC)
70 83 61 50 94 93 -58 23 17 32 49
Debt-free Net Working Capital (DFNWC)
215 242 212 231 231 244 281 137 158 134 199
Net Working Capital (NWC)
215 242 84 225 231 244 281 137 158 134 199
Net Nonoperating Expense (NNE)
-0.42 -1.95 3.71 1.99 0.92 37 -106 14 83 41 95
Net Nonoperating Obligations (NNO)
-177 -231 34 -190 42 53 -398 -170 -102 -63 -30
Total Depreciation and Amortization (D&A)
25 27 48 54 73 72 63 53 73 61 54
Debt-free, Cash-free Net Working Capital to Revenue
9.70% 11.24% 8.34% 6.74% 11.03% 14.53% -8.44% 3.32% 2.23% 3.76% 5.97%
Debt-free Net Working Capital to Revenue
29.74% 32.71% 29.02% 31.02% 27.12% 38.13% 40.62% 20.25% 20.94% 15.99% 24.11%
Net Working Capital to Revenue
29.74% 32.71% 11.55% 30.31% 27.12% 38.13% 40.62% 20.25% 20.94% 15.99% 24.11%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.12 $1.79 $0.32 $1.89 $0.06 $0.00 ($0.35) ($1.39) ($3.18) ($1.41) ($3.95)
Adjusted Weighted Average Basic Shares Outstanding
71.30M 70M 68.30M 69.40M 73.50M 0.00 78M 80.60M 82.80M 90.60M 92.60M
Adjusted Diluted Earnings per Share
$1.08 $1.71 $0.32 $1.82 $0.06 $0.00 ($0.35) ($1.39) ($3.18) ($1.41) ($3.95)
Adjusted Weighted Average Diluted Shares Outstanding
74.50M 73.40M 68.80M 72M 76M 0.00 78M 80.60M 82.80M 90.60M 92.60M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
68.60M 69.13M 68.44M 70.92M 73.87M 0.00 80.02M 81.22M 89.87M 91.31M 93.51M
Normalized Net Operating Profit after Tax (NOPAT)
79 115 30 42 5.32 -92 -89 -87 -180 -47 -47
Normalized NOPAT Margin
10.99% 15.56% 4.15% 5.71% 0.63% -14.47% -12.84% -12.76% -23.92% -5.57% -5.76%
Pre Tax Income Margin
18.59% 21.07% 4.97% 16.15% 0.00% -34.97% -8.27% -20.73% -34.81% -14.74% -47.92%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
670.50 518.00 6.83 37.97 0.73 -19.95 -7.76 -43.75 -90.28 -43.71 -36.80
NOPAT to Interest Expense
396.92 384.16 3.48 42.22 0.44 -15.02 -20.20 -30.76 -62.13 -30.88 -25.81
EBIT Less CapEx to Interest Expense
551.00 501.33 5.82 35.34 0.02 -20.90 -10.48 -57.91 -115.55 -54.32 -38.29
NOPAT Less CapEx to Interest Expense
277.42 367.49 2.47 39.59 -0.27 -15.96 -22.93 -44.91 -87.41 -41.48 -27.30
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
264.04% 138.74% 183.72% 0.00% 1,136.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Myriad Genetics

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - 91,309,064.00 92,177,383.00 93,044,627.00 93,213,722.00 93,508,165.00 94,448,210.00 95,649,645.00
DEI Adjusted Shares Outstanding
- - - - 91,309,064.00 92,177,383.00 93,044,627.00 93,213,722.00 93,508,165.00 94,448,210.00 95,649,645.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - 0.00 -3.59 -0.29 -0.08 -0.36 -0.46 -0.46
Growth Metrics
- - - - - - - - - - -
Revenue Growth
11.59% 15.26% 11.15% 7.12% -3.12% 0.76% -3.56% -0.38% 2.30% -10.51% -1.46%
EBITDA Growth
69.16% 78.89% 88.87% -41.18% -40.78% -1,352.53% -98.08% 130.42% -25.52% 91.62% -195.70%
EBIT Growth
50.76% 68.30% 65.79% -20.87% -11.15% -794.84% -10.10% 86.34% -6.23% 88.19% -75.11%
NOPAT Growth
46.55% 67.90% 66.72% -24.52% -3.94% -801.92% -16.50% 85.42% -5.86% 88.18% -71.24%
Net Income Growth
52.47% 68.39% 63.95% -36.22% 99.62% -800.55% -23.98% 81.41% -34,000.00% 86.93% -60.22%
EPS Growth
56.72% 71.13% 68.00% -38.24% 100.00% -770.73% -20.83% 80.85% 0.00% 87.11% -58.62%
Operating Cash Flow Growth
43.98% 388.89% 103.17% 112.07% 12.37% -623.08% 2,914.29% 60.61% 3.68% 38.97% -130.81%
Free Cash Flow Firm Growth
108.02% 10.13% -142.72% 13.59% -86.03% 230.19% 725.18% 1,856.44% 18,582.94% -49.39% -88.31%
Invested Capital Growth
-4.37% 4.61% 5.54% -6.24% -3.17% -44.78% -48.29% -47.00% -50.43% -17.07% -18.42%
Revenue Q/Q Growth
2.85% 4.60% 0.85% -1.27% -6.98% 8.78% -3.47% 1.99% -4.48% -4.84% 6.29%
EBITDA Q/Q Growth
39.41% -110.68% 76.04% -361.54% 39.58% -2,073.79% 96.73% 170.87% -349.32% -45.05% -4.17%
EBIT Q/Q Growth
19.00% -41.54% 43.48% -86.54% 25.52% -1,039.45% 93.05% 76.86% -479.25% -26.71% -3.08%
NOPAT Q/Q Growth
11.15% -30.82% 45.21% -95.50% 25.83% -1,035.17% 92.92% 75.54% -438.60% -26.71% -2.57%
Net Income Q/Q Growth
16.67% -41.15% 39.78% -92.31% 99.76% -330,400.00% 91.71% 71.17% -331.65% -26.69% -1.62%
EPS Q/Q Growth
14.71% -41.38% 41.46% -95.83% 100.00% 0.00% 91.88% 68.97% -300.00% -27.78% 0.00%
Operating Cash Flow Q/Q Growth
66.00% 113.98% -73.08% 842.86% -346.97% 16.56% 255.15% -49.76% -248.11% 47.13% 21.69%
Free Cash Flow Firm Q/Q Growth
-8.63% -554.81% 11.11% 130.75% -88.76% 4,138.82% 326.85% -3.76% 7.30% -88.52% -1.37%
Invested Capital Q/Q Growth
2.00% -2.71% -0.71% -4.85% 5.34% -44.51% -7.02% -2.48% -1.48% -7.17% -8.53%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
68.05% 69.55% 70.23% 71.65% 68.50% 71.23% 69.91% 69.97% 68.66% 66.60% 67.93%
EBITDA Margin
-5.09% -10.26% -2.44% -11.40% -7.40% -147.91% -5.01% 3.48% -9.08% -13.84% -13.57%
Operating Margin
-13.80% -17.26% -9.38% -18.57% -14.80% -154.48% -11.33% -2.72% -15.32% -20.40% -19.68%
EBIT Margin
-12.86% -17.40% -9.75% -18.42% -14.75% -154.53% -11.13% -2.53% -15.32% -20.40% -19.78%
Profit (Net Income) Margin
-12.86% -17.35% -10.36% -20.18% -0.05% -155.09% -13.32% -3.77% -17.02% -22.65% -21.66%
Tax Burden Percent
100.39% 98.66% 104.25% 108.42% 0.34% 99.97% 104.58% 88.76% 100.00% 101.41% 100.69%
Interest Burden Percent
99.62% 101.09% 101.92% 101.03% 101.73% 100.39% 114.41% 167.92% 111.07% 109.51% 108.73%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-10.53% -14.67% -8.28% -16.50% -12.61% -171.77% -12.86% -3.21% -17.68% -33.75% -35.16%
ROIC Less NNEP Spread (ROIC-NNEP)
-3.12% -0.22% 6.63% 1.81% -53.79% 78.69% 12.69% 5.24% 51.23% 302.46% 233.25%
Return on Net Nonoperating Assets (RNNOA)
0.34% 0.02% -0.51% -0.20% 3.60% -5.57% -1.00% -0.45% -1.80% -4.15% -4.32%
Return on Equity (ROE)
-10.19% -14.65% -8.78% -16.71% -9.00% -177.34% -13.86% -3.66% -19.48% -37.90% -39.48%
Cash Return on Invested Capital (CROIC)
-18.51% -21.03% -17.80% -6.66% -9.54% 1.98% 5.79% 5.93% 13.30% -1.56% -5.32%
Operating Return on Assets (OROA)
-8.73% -12.29% -7.20% -14.20% -11.59% -146.06% -10.16% -2.40% -15.12% -25.00% -23.78%
Return on Assets (ROA)
-8.73% -12.25% -7.65% -15.55% -0.04% -146.59% -12.15% -3.58% -16.80% -27.77% -26.03%
Return on Common Equity (ROCE)
-10.19% -14.65% -8.78% -16.71% -9.00% -177.34% -13.86% -3.66% -19.48% -37.90% -39.48%
Return on Equity Simple (ROE_SIMPLE)
-30.87% -20.96% -15.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-20 -26 -14 -27 -20 -230 -16 -3.99 -21 -27 -28
NOPAT Margin
-9.66% -12.08% -6.56% -13.00% -10.36% -108.14% -7.93% -1.90% -10.72% -14.28% -13.78%
Net Nonoperating Expense Percent (NNEP)
-7.41% -14.45% -14.90% -18.32% 41.18% -250.46% -25.55% -8.45% -68.91% -336.21% -268.40%
Return On Investment Capital (ROIC_SIMPLE)
-2.45% -3.28% -1.82% -3.70% -2.66% -51.50% -3.31% -0.82% -4.70% -6.41% -7.16%
Cost of Revenue to Revenue
31.95% 30.45% 29.77% 28.35% 31.50% 28.77% 30.09% 30.03% 31.34% 33.40% 32.07%
SG&A Expenses to Revenue
69.54% 68.51% 65.21% -70.61% 33.95% 31.35% 33.01% 26.50% 31.04% 30.31% 33.15%
R&D to Revenue
12.31% 12.81% 13.36% 15.62% 14.04% 12.01% 13.71% 12.15% 13.52% 13.11% 13.07%
Operating Expenses to Revenue
81.85% 86.81% 79.61% 90.22% 83.31% 225.72% 81.23% 72.69% 83.98% 87.00% 87.62%
Earnings before Interest and Taxes (EBIT)
-26 -37 -21 -39 -29 -329 -23 -5.30 -31 -39 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-10 -22 -5.20 -24 -15 -315 -10 7.30 -18 -26 -28
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.31 2.99 3.40 1.78 1.15 1.26 1.80 1.56 1.25 1.77 1.53
Price to Tangible Book Value (P/TBV)
13.27 16.44 18.72 8.19 5.03 2.94 4.26 3.52 2.91 4.58 4.58
Price to Revenue (P/Rev)
2.26 2.76 3.02 1.49 0.97 0.59 0.82 0.70 0.51 0.67 0.51
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.43 3.19 3.62 1.86 1.16 1.27 1.86 1.61 1.25 1.76 1.51
Enterprise Value to Revenue (EV/Rev)
2.18 2.69 2.95 1.42 0.94 0.57 0.78 0.66 0.50 0.68 0.53
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 301.98 173.62 70.75 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 45.67 21.94 18.77 6.23 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.05 0.05 0.05 0.06 0.08 0.15 0.32 0.33 0.36 0.40 0.45
Long-Term Debt to Equity
0.05 0.05 0.05 0.06 0.08 0.00 0.32 0.33 0.36 0.40 0.45
Financial Leverage
-0.11 -0.10 -0.08 -0.11 -0.07 -0.07 -0.08 -0.09 -0.04 -0.01 -0.02
Leverage Ratio
1.43 1.54 1.58 1.46 1.44 1.56 1.64 1.62 1.61 1.90 2.08
Compound Leverage Factor
1.42 1.56 1.61 1.48 1.47 1.57 1.87 2.72 1.79 2.08 2.27
Debt to Total Capital
4.85% 4.98% 5.06% 5.35% 7.76% 13.27% 24.27% 24.57% 26.28% 28.43% 31.04%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 13.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
4.85% 4.98% 5.06% 5.35% 7.76% 0.00% 24.27% 24.57% 26.28% 28.43% 31.04%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
95.15% 95.02% 94.94% 94.65% 92.24% 86.73% 75.73% 75.43% 73.72% 71.57% 68.96%
Debt to EBITDA
-0.22 -0.41 -0.72 -0.65 -0.91 -0.17 -0.33 -0.36 -0.36 -2.54 -1.87
Net Debt to EBITDA
0.37 0.61 1.12 1.03 0.50 0.04 0.07 0.09 0.01 -0.12 -0.22
Long-Term Debt to EBITDA
-0.22 -0.41 -0.72 -0.65 -0.91 0.00 -0.33 -0.36 -0.36 -2.54 -1.87
Debt to NOPAT
-0.24 -0.36 -0.48 -0.46 -0.68 -0.20 -0.41 -0.44 -0.44 -1.75 -1.50
Net Debt to NOPAT
0.40 0.54 0.75 0.73 0.37 0.05 0.09 0.11 0.02 -0.08 -0.17
Long-Term Debt to NOPAT
-0.24 -0.36 -0.48 -0.46 -0.68 0.00 -0.41 -0.44 -0.44 -1.75 -1.50
Altman Z-Score
2.95 3.75 4.20 2.11 1.45 -1.46 0.35 0.27 -0.25 -0.30 -0.77
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.99 1.96 1.90 1.82 1.90 1.42 2.33 2.49 2.40 2.21 1.98
Quick Ratio
1.52 1.44 1.46 1.36 1.40 1.06 1.78 1.98 1.91 1.72 1.55
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
12 -55 -49 15 1.70 72 308 296 318 36 36
Operating Cash Flow to CapEx
-216.28% 29.21% 11.11% 111.86% -307.55% -485.71% 753.57% 225.53% -290.74% -395.24% -361.11%
Free Cash Flow to Firm to Interest Expense
24.34 -69.19 -61.50 21.61 2.13 48.04 80.94 67.28 77.47 8.90 8.77
Operating Cash Flow to Interest Expense
-37.20 3.25 0.88 9.43 -20.38 -9.07 5.55 2.41 -3.83 -2.02 -1.59
Operating Cash Flow Less CapEx to Interest Expense
-54.40 -7.88 -7.00 1.00 -27.00 -10.93 4.82 1.34 -5.15 -2.54 -2.02
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.68 0.71 0.74 0.77 0.79 0.95 0.91 0.95 0.99 1.23 1.20
Accounts Receivable Turnover
6.53 6.99 6.84 7.11 6.97 6.54 6.77 6.97 6.79 6.54 7.19
Inventory Turnover
10.41 10.21 9.91 10.19 9.43 8.99 8.46 8.53 8.86 8.48 8.46
Fixed Asset Turnover
7.21 7.03 6.98 7.09 7.15 7.26 7.28 7.13 7.35 7.27 7.44
Accounts Payable Turnover
6.94 6.79 8.00 8.68 8.15 7.67 7.97 7.96 8.20 8.20 8.57
Days Sales Outstanding (DSO)
55.91 52.21 53.38 51.31 52.36 55.83 53.89 52.35 53.76 55.77 50.76
Days Inventory Outstanding (DIO)
35.05 35.74 36.84 35.82 38.73 40.62 43.13 42.77 41.19 43.05 43.17
Days Payable Outstanding (DPO)
52.57 53.75 45.61 42.04 44.80 47.59 45.81 45.86 44.49 44.50 42.60
Cash Conversion Cycle (CCC)
38.39 34.20 44.62 45.09 46.28 48.86 51.20 49.26 50.46 54.32 51.33
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
694 676 671 638 672 373 347 338 333 309 283
Invested Capital Turnover
1.09 1.21 1.26 1.27 1.22 1.59 1.62 1.69 1.65 2.36 2.55
Increase / (Decrease) in Invested Capital
-32 30 35 -43 -22 -303 -324 -300 -339 -64 -64
Enterprise Value (EV)
1,687 2,155 2,427 1,185 777 474 647 544 417 545 426
Market Capitalization
1,752 2,214 2,488 1,248 810 489 673 573 421 539 412
Book Value per Share
$8.45 $8.18 $8.06 $7.70 $7.72 $4.21 $4.01 $3.95 $3.61 $3.22 $2.81
Tangible Book Value per Share
$1.47 $1.49 $1.46 $1.67 $1.76 $1.81 $1.70 $1.75 $1.55 $1.25 $0.94
Total Capital
799 779 771 741 764 448 492 488 458 425 390
Total Debt
39 39 39 40 59 59 120 120 120 121 121
Total Long-Term Debt
39 39 39 40 59 0.00 120 120 120 121 121
Net Debt
-66 -59 -61 -63 -33 -15 -26 -30 -4.10 5.50 14
Capital Expenditures (CapEx)
8.60 8.90 6.30 5.90 5.30 2.80 2.80 4.70 5.40 2.10 1.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)
40 45 39 32 44 69 51 49 58 43 27
Debt-free Net Working Capital (DFNWC)
144 143 139 134 136 144 197 199 183 158 134
Net Working Capital (NWC)
144 143 139 134 136 84 197 199 183 158 134
Net Nonoperating Expense (NNE)
6.47 11 8.10 15 -20 100 11 3.91 13 16 16
Net Nonoperating Obligations (NNO)
-66 -65 -61 -63 -33 -15 -26 -30 -4.10 5.50 14
Total Depreciation and Amortization (D&A)
16 15 16 15 14 14 13 13 13 13 13
Debt-free, Cash-free Net Working Capital to Revenue
5.15% 5.66% 4.74% 3.76% 5.33% 8.33% 6.23% 5.97% 7.02% 5.34% 3.38%
Debt-free Net Working Capital to Revenue
18.63% 17.79% 16.87% 15.99% 16.37% 17.27% 23.85% 24.11% 22.03% 19.63% 16.71%
Net Working Capital to Revenue
18.63% 17.79% 16.87% 15.99% 16.37% 10.13% 23.85% 24.11% 22.03% 19.63% 16.71%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.29) ($0.41) ($0.24) ($0.47) $0.00 ($3.57) ($0.29) ($0.09) ($0.36) ($0.46) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding
89.90M 90.60M 90.90M 90.60M 91.40M 92.50M 93.10M 92.60M 93.70M 94.80M 95.70M
Adjusted Diluted Earnings per Share
($0.29) ($0.41) ($0.24) ($0.47) $0.00 ($3.57) ($0.29) ($0.09) ($0.36) ($0.46) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding
89.90M 90.60M 90.90M 90.60M 91.40M 92.50M 93.10M 92.60M 93.70M 94.80M 95.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
90.51M 90.82M 91.04M 91.31M 92.18M 93.04M 93.21M 93.51M 94.45M 95.65M 95.92M
Normalized Net Operating Profit after Tax (NOPAT)
-20 -17 -12 -27 -20 -8.75 -16 -2.10 -18 -27 -28
Normalized NOPAT Margin
-9.66% -8.24% -5.84% -13.00% -10.36% -4.11% -7.93% -1.00% -8.84% -14.28% -13.78%
Pre Tax Income Margin
-12.81% -17.59% -9.94% -18.61% -15.01% -155.14% -12.74% -4.24% -17.02% -22.34% -21.51%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-52.00 -46.00 -26.00 -55.43 -36.13 -219.53 -6.03 -1.20 -7.49 -9.49 -9.78
NOPAT to Interest Expense
-39.06 -31.94 -17.50 -39.10 -25.38 -153.63 -4.29 -0.91 -5.24 -6.64 -6.81
EBIT Less CapEx to Interest Expense
-69.20 -57.13 -33.88 -63.86 -42.75 -221.40 -6.76 -2.27 -8.80 -10.00 -10.22
NOPAT Less CapEx to Interest Expense
-56.26 -43.06 -25.38 -47.53 -32.00 -155.49 -5.03 -1.98 -6.56 -7.15 -7.25
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Myriad Genetics’ latest results show improving losses from the severe impairment-driven comparison period, but the underlying business remains under pressure. Revenue declined to $190.7 million in Q2 2026 from $213.1 million in the restated Q2 2025, while gross margin fell to approximately 66.6% from 71.2%. The company has reported a net loss in every quarter provided since Q3 2022.

  • Liquidity remains adequate. Myriad ended Q2 2026 with $115.2 million of cash and $289.0 million of current assets versus $130.7 million of current liabilities, producing a current ratio of roughly 2.2.
  • The year-over-year net loss improved substantially. Q2 2026 net loss was $43.2 million, compared with a $330.5 million loss in Q2 2025. However, the prior-year period included a $316.7 million impairment charge, so the comparison is heavily affected by a noncash item.
  • Operating expenses declined modestly sequentially. Total operating expenses decreased to $165.9 million in Q2 2026 from $168.3 million in Q1 2026, helped by lower selling, general and administrative and research and development expenses.
  • Operating cash flow has been volatile. Myriad generated $21.1 million of operating cash flow in Q3 2025, but used $13.6 million in Q2 2025, $15.7 million in Q1 2026 and $8.3 million in Q2 2026. The recent improvement is encouraging, but does not yet establish a consistent positive trend.
  • Investment spending has moderated. Capital expenditures were $2.1 million in Q2 2026, down from $5.4 million in Q1 2026 and $8.9 million in Q2 2024. Lower spending helps preserve cash, although it may also reflect more cautious investment in future growth.
  • Revenue has weakened over the past year. Q2 2026 revenue fell 10.5% year over year and was also below Q1 2026 revenue of $200.4 million. Revenue has generally remained in the $180 million to $213 million quarterly range rather than showing sustained growth.
  • Myriad remains unprofitable at the operating level. The company posted a $38.9 million operating loss in Q2 2026, following losses of $30.7 million in Q1 2026, $23.3 million in Q3 2025 and $5.7 million in Q4 2025.
  • Cost pressure is compressing margins. Gross profit declined to $127.0 million in Q2 2026 from $151.8 million in Q2 2025, and the gross margin fell by about 4.6 percentage points. Marketing expense also increased to $83.1 million in Q2 2026, representing more than 43% of revenue.
  • Cash reserves are trending lower. Cash declined from $145.4 million in Q3 2025 to $115.2 million in Q2 2026, including a $22.2 million quarterly reduction in Q2. Continued operating losses could force the company to rely more heavily on financing.
  • The balance sheet reflects substantial accumulated losses and debt. Retained earnings were negative $1.2 billion at Q2 2026, while long-term debt was $120.7 million. Total assets have also fallen from more than $1.0 billion in early 2025 to $638.9 million, partly because of impairment charges and declining intangible-asset balances.

For investors, the key issue is whether Myriad can reverse the recent revenue decline and reach operating break-even before its cash balance is materially depleted. The large year-over-year improvement in net loss is a positive headline, but it largely reflects the absence of the prior-year impairment charge rather than a return to profitability. The continuing operating losses, lower gross margin and recent cash usage remain significant risks.

11/17/26 05:21 AM ETAI Generated. May Contain Errors.

Myriad Genetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Myriad Genetics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Myriad Genetics' net income appears to be on a downward trend, with a most recent value of -$365.90 million in 2025, compared with $79.80 million in 2015. The previous period was -$127.30 million in 2024. View Myriad Genetics' forecast to see where analysts expect Myriad Genetics to go next.

Myriad Genetics' total operating income in 2025 was -$387.20 million, based on the following breakdown:
  • Total Gross Profit: $576.60 million
  • Total Operating Expenses: $963.80 million

Over the last 10 years, Myriad Genetics' total revenue changed from $722.50 million in 2015 to $824.50 million in 2025, a change of 14.1%.

In the past 13 quarters, Myriad Genetics' cash and equivalents has ranged from $74.40 million in Q2 2025 to $145.40 million in Q3 2025, and is currently $107.10 million as of their latest financial filing in Q3 2026.

Myriad Genetics had total debt of $119.90 million at the end of 2025, a 202.8% increase from 2024, and a 1,262.5% increase since 2015.

Over the last 10 years, Myriad Genetics' book value per share changed from 9.53 in 2015 to 3.95 in 2025, a change of -58.6%.



Financial statements for NASDAQ:MYGN last updated on 11/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners